Notal Vision
Elior Cohen has extensive work experience in software development and engineering. Elior started working at Elbit Systems Ltd in 2012 as a Software Engineer, responsible for developing software in various programming languages. In 2016, they became the Engineering Process Tools Site Team Leader, managing a team of 5 employees and overseeing application development and production issues. In 2017, Elior joined Notal Vision as a Software Developer and later became the SW team leader. Currently, they are serving as the Director of Cloud Software Development at Notal Vision.
Elior Cohen attended Ben-Gurion University of the Negev from 2010 to 2014, earning a Bachelor of Science (BSc) degree. Additionally, Elior pursued studies at the same institution for an unknown period, completing a Bachelor of Applied Science (BASc) degree. The specific field of study for both degrees is unknown.
This person is not in any offices
Notal Vision
Notal Vision is a patient-centric ophthalmic remote monitoring services provider extending retinal disease monitoring from the clinic to the home, providing physicians with remote monitoring services to support their patient care between office visits. With a proven approach to home-based, self-operated diagnostics, AI-enabled data analysis, and patient engagement, we help preserve patients’ vision. The Notal Vision Monitoring Center is a remote, Medicare credentialed ophthalmic provider and the epicenter of patient engagement. Led by practicing ophthalmologists and supported by certified ophthalmic professionals, the Monitoring Center offers a comprehensive nationwide age-related macular degeneration (AMD) home monitoring service for referred patients. The ForeseeHome® AMD Monitoring Program helps physicians detect the conversion to wet AMD early, leading to earlier treatment intervention and better visual outcomes. Our Home OCT pipeline technology will provide patient-initiated retinal OCT scans to support the management of patients with neovascular retinal diseases, complementing existing in-office imaging and standard of care treatments as well as emerging longer acting drugs and drug delivery systems.